Benzodiazepines Inhibit the Acetylcholine Receptor-Operated Potassium Current (IK.Ach) by Different Mechanisms in Guinea-Pig Atrial Myocytes

Total Page:16

File Type:pdf, Size:1020Kb

Benzodiazepines Inhibit the Acetylcholine Receptor-Operated Potassium Current (IK.Ach) by Different Mechanisms in Guinea-Pig Atrial Myocytes FULL PAPER Pharmacology Benzodiazepines Inhibit the Acetylcholine Receptor-Operated Potassium Current (IK.ACh) by Different Mechanisms in Guinea-pig Atrial Myocytes Muneyoshi OKADA1), Wataru MIZUNO1), Ryu NAKARAI1), Takashi MATADA1), Hideyuki YAMAWAKI1) * and Yukio HARA1) 1)Laboratory of Veterinary Pharmacology, Kitasato University, Towada, Aomori 034–8628, Japan (Received 30 November 2011/Accepted 31 January 2012/Published online in J-STAGE 14 February 2012) ABSTRACT. The anticholinergic effects of 7 benzodiazepines, bromazepam, camazepam, chlordiazepoxide, diazepam, lorazepam, medazepam and triazolam, were compared by examining their inhibitory effects on the acetylcholine receptor-operated potassium current (IK.ACh) in guinea-pig atrial myocytes. All of these benzodiazepines (0.3–300 µM) inhibited carbachol (1 µM)-induced IK.ACh in a concentration-dependent manner. The ascending order of IC50 values for carbachol-induced IK.ACh was as follows; medazepam, diazepam, camazepam, triazolam, bromazepam, lorazepam and chlordiazepoxide (>300 µM). The compounds, except for bromaze- pam, also inhibited IK.ACh activated by an intracellular loading of 100 µM guanosine 5’-[γ-thio]triphosphate (GTPγS) in a concen- tration-dependent manner. The ascending order of IC50 values for GTPγS-activated IK.ACh was as follows; medazepam, diazepam, camazepam, lorazepam, triazolam chlordiazepoxide (>300 µM) and bromazepam (>300 µM). To clarify the molecular mechanism of the inhibition, IC50 ratio, the ratio of IC50 for GTPγS-activated IK.ACh to carbachol-induced IK.ACh, was calculated. The IC50 ratio for camazepam, diazepam, lorazepam, medazepam and triazolam was close to unity, while it for chlordiazepoxide could not be cal- culated. These compounds would act on the GTP binding protein and/or potassium channel to achieve the anticholinergic effects in atrial myocytes. In contrast, since the IC50 ratio for bromazepam is presumably much higher than unity judging from the IC50 values (104.0 ± 30.0 µM for carbachol-induced IK.ACh and >300 µM for GTPγS-activated IK.ACh), it would act on the muscarinic receptor. In summary, benzodiazepines had the anticholinergic effects on atrial myocytes through inhibiting IK.ACh by different molecular mecha- nisms. KEY WORDS: acetylcholine receptor-operated potassium current, atrial myocyte, benzodiazepines, bromazepam, patch clamp method. doi: 10.1292/jvms.11-0538; J. Vet. Med. Sci. 74 (7): 879–884, 2012 Benzodiazepine derivatives are established therapeutic are presumed to affect the ionic currents in the heart. How- tools with relatively low incidence of adverse effects in hu- ever, there is no data available determining the effects of man and veterinary medicine and are used as preanesthetics, benzodiazepines on cardiac ligand-gated currents. tranquilizers, muscle relaxants, and anticonvulsant agents The acetylcholine receptor-operated potassium current [6]. In veterinary clinical fields, benzodiazepine deriva- (IK.ACh), a ligand-gated potassium current, has been known tives are also utilized for animal behavior disorders [17]. to play an important role in the repolarization of the action Virtually, no cardiac effect is observed after ingestion of potential as well as maintenance of the resting potential in therapeutic doses of diazepam in otherwise healthy patients atrial cells [20]. In atrial cells with chronic atrial fibrillation, [2]. While previous in vitro studies have suggested that di- IK.ACh was constitutively active without muscarinic receptor azepam could affect cardiac contractility, the data and their stimulation [7]. The inhibition of IK.ACh appears to be one of interpretation are rather contradictory. For example, both the mechanisms for the termination and prevention of atrial positive and negative inotropic actions, biphasic inotropic flutter and fibrillation [4]. Thus, to explore the influence action, and no effect of diazepam have been reported in dif- of benzodiazepine derivatives on IK.ACh is of great clinical ferent species of animals using various ranges of concentra- significance. In the present study, influences of 7 benzo- tions [1, 5, 8, 23]. Our previous studies have provided one diazepine derivatives including diazepam on IK.ACh were explanation for this contradiction, i.e., diazepam produced examined by a whole-cell patch clamp method in guinea the negative inotropic effect in isolated guinea pig heart pig atrial myocytes. And mechanisms of the anticholinergic through inhibition of the calcium current [15], while at the action of benzodiazepines were explored. same time, it increased calcium sensitivity of the cardiac muscle fiber in the same concentration ranges [13]. From MATERIALS AND METHODS these reports about diazepam, benzodiazepine derivatives This study was performed in compliance with the “Guid- ing Principles for the Care and Use of Laboratory Animals” *CORRESPONDENCE TO: YAMAWAKI, H., Laboratory of Veterinary Pharmacology, Kitasato University, Higashi 23 bancho, 35–1, approved by the Japanese Pharmacological Society and Towada, Aomori 034–8628, Japan. the Kitasato University. The methods for cell prepara- e-mail: [email protected] tions and current recordings were the same as the previous ones [12, 16]. Briefly, guinea-pig (male, 250–750 g body © The Japanese Society of Veterinary Science 880 M. OKADA ET AL. weight) hearts were isolated under sodium pentobarbital carbachol (1 µM) in the GTP (100 µM)-loaded atrial myo- (50 mg/kg i.p. injection) anesthesia and set on a modified cytes using the whole-cell mode of patch clamp method at Langendorff apparatus for isolation of single atrial myocytes a holding potential of −40 mV. After induction of IK.ACh, by an enzymatic digestion with collagenase. Whole-cell benzodiazepines were added to the bath solution in the patch clamp method was used for recording of IK.ACh as an presence of carbachol. Concentration of benzodiazepines outward current at a holding potential of −40 mV. IK.ACh was increased in a stepwise fashion every 3 min. All of was induced by a superfusion of 1 µM carbachol or by an the benzodiazepines used in the present study inhibited the intracellular application of 100 µM guanosine 5’-[γ-thio] carbachol-induced IK.ACh effectively in a concentration- triphosphate (GTPγS), a nonhydrolysable guanosine 5’-tri- dependent manner (Figs. 1 and 3). The outward current reap- phosphate (GTP) analogue. The normal N-[2-hydroxyethyl] peared after a wash-out of each drug. Inhibitory effect of the piperazine-N’-[2-ethanesulfonic acid (HEPES)-Tyrode solu- maximum concentration of chlordiazepoxide (300 µM) on tion (pH 7.4) and the standard pipette solution were used as the current was weak and did not attain 50% inhibition (45.2 superfusate and inner solution, respectively. The composi- ± 4.8% inhibition, n=8). The IC50 values for the carbachol- tion of HEPES-Tyrode solution was (mM): NaCl 143, KCl induced IK.ACh are shown in Table 1. The ascending order of 5.4, CaCl2 1.8, MgCl2 0.5, NaH2PO4 0.33, glucose 5.5 and IC50 values for the carbachol-induced IK.ACh was as follows; HEPES 5.0. The composition of the standard pipette solution medazepam (12.9 ± 2.4 µM), diazepam (54.8 ± 10.7 µM), was (mM): K-aspartate 110, KCl 20, MgCl2 1.0, GTP 0.1, camazepam (85.6 ± 7.5 µM), triazolam (93.1 ± 21.8 µM), adenosine-5’-triphosphate (ATP)-K 5.0, ethylene glycol-bis bromazepam (104.0 ± 30.0 µM), lorazepam (134.3 ± 4.6 (2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA) 10 µM) and chlordiazepoxide (>300 µM; 45.2 ± 4.8% inhibi- and HEPES 5.0 (pH 7.4, free Ca2+ concentration, pCa 8). tion at 300 µM). All benzodiazepines, bromazepam, camazepam, chlordi- Effects of 7 benzodiazepines on the GTPγS-activated azepoxide, diazepam, lorazepam, medazepam and triazolam, IK.ACh in a single guinea pig atrial myocyte: Effects of 7 are obtained from the Yamanouchi Pharmaceutical Co., Ltd. benzodiazepines (0.3–300 µM) on the the GTPγS-activated (Tokyo, the present company name is Astellas Pharm Inc.) IK.ACh were examined. In these experiments, the pipet solu- and are dissolved in dimethyl sulfoxide (DMSO) as a stock tion containing 100 µM GTPγS instead of GTP was used. solution. The final concentration of DMSO is less than 1% Intracellular loading of GTPγS in atrial myocytes gradually and this concentration of DMSO did not affect IK.ACh record- activated the outward current, i.e., IK.ACh, at a holding poten- ing. tial of −40 mV. Camazepam, diazepam, lorazepam, medaz- Data analysis: In the recordings of the IK.ACh current, the epam and triazolam inhibited the GTPγS-activated IK.ACh in activated current is followed by a continuous decline by a concentration-dependent manner (Figs. 2 and 3). Bromaze- the desensitization [22]. Continuous current decline before pam produced only a slight inhibition of the current even at benzodiazepine derivative treatment was assumed as quasi- the highest concentration (12.6 ± 2.5% inhibition, n=6, at steady state (QSS). We used QSS as a maximum current. 300 µM, Figs. 2 and 3). Chlordiazepoxide 300 µM inhibited All values are presented as mean ± standard error of mean the current by 33.1 ± 7.4% (n=6). The IC50 values for the (S.E.M.). The concentrations required to produce 50% of GTPγS-activated IK.ACh are shown in Table 1. The ascending the maximal inhibitory effect (IC50) were calculated from order of IC50 values for the GTPγS-activated IK.ACh was as concentration-response curves using Math Curve Fitter (Sig- follows; medazepam (20.7 ± 3.6 µM), diazepam (75.9 ± 9.1 maPlot, Systat Software, Inc., San Jose, CA, U.S.A.) to solve µM), camazepam (81.6 ± 5.9 µM), lorazepam (98.8 ± 3.4 nonlinear equations. For comparison of IC50 value, statistical µM), triazolam (125.3 ± 25.5 µM), chlordiazepoxide (>300 analyses were performed using un-paired Student’s t-test. A µM; 33.1 ± 7.4% inhibition at 300 µM) and bromazepam value of P<0.05 was considered to be statistically signifi- (>300 µM; 12.6 ± 2.5% inhibition at 300 µM).
Recommended publications
  • Ionization Energies of Benzodiazepines Salvatore Millefiori, Andrea Alparone
    Electronic properties of neuroleptics: ionization energies of benzodiazepines Salvatore Millefiori, Andrea Alparone To cite this version: Salvatore Millefiori, Andrea Alparone. Electronic properties of neuroleptics: ionization energies of benzodiazepines. Journal of Molecular Modeling, Springer Verlag (Germany), 2010, 17 (2), pp.281- 287. 10.1007/s00894-010-0723-7. hal-00590996 HAL Id: hal-00590996 https://hal.archives-ouvertes.fr/hal-00590996 Submitted on 6 May 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Editorial Manager(tm) for Journal of Molecular Modeling Manuscript Draft Manuscript Number: JMMO1191R1 Title: Electronic properties of neuroleptics: ionization energies of benzodiazepines Article Type: Original paper Keywords: Benzodiazepines; vertical ionization energies; vertical electron affinities; DFT calculations; electron propagator theory calculations. Corresponding Author: Prof. Salvatore Millefiori, Corresponding Author's Institution: First Author: Salvatore Millefiori Order of Authors: Salvatore Millefiori; Andrea Alparone Abstract: Abstract. Vertical ionization energies (VIEs) of medazepam and nordazepam and of their molecular subunits have been calculated with the electron propagator method in the P3/CEP-31G* approximation. Vertical electron affinities (VEAs) have been obtained with a ΔSCF procedure at the DFT-B3LYP/6-31+G* level of theory. Excellent correlations have been achieved between IEcalc and IEexp allowing reliable assignment of the ionization processes.
    [Show full text]
  • Understanding Benzodiazephine Use, Abuse, and Detection
    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
    [Show full text]
  • Retention Behaviour of Some Benzodiazepines in Solid-Phase Extraction Using Modified Silica Adsorbents Having Various Hydrophobicities
    ACADEMIA ROMÂNĂ Rev. Roum. Chim., Revue Roumaine de Chimie 2015, 60(9), 891-898 http://web.icf.ro/rrch/ RETENTION BEHAVIOUR OF SOME BENZODIAZEPINES IN SOLID-PHASE EXTRACTION USING MODIFIED SILICA ADSORBENTS HAVING VARIOUS HYDROPHOBICITIES Elena BACALUM,a Mihaela CHEREGIb,* and Victor DAVIDb,* a Research Institute from University of Bucharest – ICUB, 36-46 M. Kogalniceanu Blvd., Bucharest, 050107, Roumania b University of Bucharest, Faculty of Chemistry, Department of Analytical Chemistry, 90 Panduri Ave, Bucharest – 050663, Roumania Received April 6, 2015 The retention properties of six benzodiazepines (alprazolam, bromazepam, diazepam, flunitrazepam, medazepam, and nitrazepam) on four different solid phase extraction silica 1.0 adsorbents with various hydrophobicities (octadecylsilica, octylsilica, phenylsilica, and cyanopropylsilica) were 0.8 H O investigated. The breakthrough curves showed a significant N retention of these compounds on octadecylsilica, octylsilica, 0.6 Br N phenylsilica, excepting alprazolam that has a poor retention on 0 C/C N octadecylsilica. These results can be explained by the 0.4 PHENYL CN hydrophobic character of studied benzodiazepines (octanol- C18 0.2 C8 Bromazepam water partition constant, log Kow, being situated within the interval 1.90-4.45). A poor retention on cyanopropylsilica was 0.0 observed for all studied compounds indicating that π-π and 0 102030405060708090100 Volume (mL) polar intermolecular interactions have a less significant role in their retention on this adsorbent. Generally, the breakthrough
    [Show full text]
  • Benzodiazepines in Chronic Pain Why the Interest?
    Why the Interest? • 33 years in chronic pain rehabilitation Benzodiazepines • Many patients are dysfunctional, depressed, in Chronic Pain regressed, and cognitively impaired while taking opioids plus benzodiazepines. • Engendered a negative attitude Edward Covington, MD • Stimulated curiosity about what we Cleveland Clinic Foundation do and do not know about these drugs in pain patients, especially in combination with opioids Disclaimer History Much of the data that I could find is quite old • For centuries, humans have sought anxiolysis, euphoria • Alcohol was followed by sedatives and anxiolytics • 19th century – Bromides (“take a powder”), choral hydrate (Mickey Finn), paraldehyde • Barbiturates synthesized in 1903 • Meprobamate in 1950 Benzodiazepine Introduction Benzodiazepine Use in America • Chlordiazepoxide introduced in 1960 • BZs are the most prescribed CNS depressants • Addictiveness and lethality of barbiturates (and similar drugs) led to their replacement by BZs • Estimated past year prevalence of BZ use in • Use of BZs increased dramatically the USA = 12.9% – US sales peaked in 1975 – Anxiolytics / hypnotics accounted for 10% of all • 14.2% of these have taken the drug ≥ 12 mo prescriptions Barker MJ et al. Arch Clin Neuropsychology 2004;19:437-454 • WHO recommended scheduling BZs in the early • About 100 million prescriptions in 1999 1980s DEA Lader, M: J Subs Abuse Treatment 1991;8:53-59 1 Mechanism of Tranquilization How Reinforcing are BZs? - • GABA binding permits Cl influx Humans • Hyperpolarizes cell, •Normal (light
    [Show full text]
  • Analytical Methods for Determination of Benzodiazepines. a Short Review
    Cent. Eur. J. Chem. • 12(10) • 2014 • 994-1007 DOI: 10.2478/s11532-014-0551-1 Central European Journal of Chemistry Analytical methods for determination of benzodiazepines. A short review Review Article Paulina Szatkowska1, Marcin Koba1*, Piotr Kośliński1, Jacek Wandas1, Tomasz Bączek2,3 1Department of Toxicology, Faculty of Pharmacy, Collegium Medicum of Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland 3Institute of Health Sciences, Division of Human Anatomy and Physiology, Pomeranian University of Słupsk, 76-200 Słupsk, Poland Received 16 July 2013; Accepted 6 February 2014 Abstract: Benzodiazepines (BDZs) are generally commonly used as anxiolytic and/or hypnotic drugs as a ligand of the GABAA-benzodiazepine receptor. Moreover, some of benzodiazepines are widely used as an anti-depressive and sedative drugs, and also as anti-epileptic drugs and in some cases can be useful as an adjunct treatment in refractory epilepsies or anti-alcoholic therapy. High-performance liquid chromatography (HPLC) methods, thin-layer chromatography (TLC) methods, gas chromatography (GC) methods, capillary electrophoresis (CE) methods and some of spectrophotometric and spectrofluorometric methods were developed and have been extensively applied to the analysis of number of benzodiazepine derivative drugs (BDZs) providing reliable and accurate results. The available chemical methods for the determination of BDZs in biological materials and pharmaceutical formulations are reviewed in this work. Keywords: Analytical methods • Benzodiazepines • Drugs analysis • Pharmaceutical formulations © Versita Sp. z o.o. 1. Introduction and long). For this reason, an application of these drugs became broader allowing their utility to a larger extent, Benzodiazepines have been first introduced into medical and at the same time, problems related to drug abuse practice in the 60s of the last century.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • An Inventory of Literature on the Relation Between Drug Use, Impaired Driving and Traffic Accidents
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by National Documentation Centre on Drug Use E.M.C.D.D.A. DRUGS MISUSE RESEARCH DIVISION HEALTH RESEARCH BOARD An Inventory of Literature on the Relation between Drug Use, Impaired Driving and Traffic Accidents CT.97.EP.14 Research Team: Colin Gemmell Trinity College, Dublin Rosalyn Moran Drugs Misuse Research Division, Health Research Board James Crowley Professor, Transport Policy Research Institute, University College Dublin Richeal Courtney Medical Expert, for the Health Research Board EMCDDA: Lucas Wiessing February 1999 Please use the following citation: European Monitoring Centre for Drugs and Drug Addiction. An Inventory of Literature on the Relation betweenDrug Use, Impaired Driving and Traffic Accidents. (CT.97.EP.14) Lisbon: EMCDDA, February 1999. Contact Details Drugs Misuse Research Division Health Research Board 73 Lower Baggot Street Dublin 2 Ireland European Monitoring Centre for Drugs and Drug Addiction Rua Cruz de Santa Apolónia 23/25 1100, Lisboa Portugal. Further copies of this bibliography can be obtained from the EMCDDA at the above address. CREDITS Principal Researchers Ms Rosalyn Moran, Project Leader, Health Research Board Professor James Crowley, Professor, Transport Policy Research Institute, UCD Dr Richeal Courtney, Medical Expert, on behalf of the Health Research Board Research Assistants Colin Gemmell (Synthesis and Final Reports) Sarah Heywood (Literature Search and Collaborative Network) For the EMCDDA Lucas Wiessing
    [Show full text]
  • Apo-Bromazepam
    PRODUCT MONOGRAPH APO-BROMAZEPAM bromazepam 1.5 mg, 3 mg and 6 mg Tablets Anxiolytic - Sedative APOTEX INC. Date of Revision: 150 Signet Drive March 10, 2016 Toronto, Ontario M9L 1T9 Control No.: 192477 1 Table of Contents PART I: HEALTH PROFFESSIONAL INFORMATION .................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 4 WARNINGS AND PRECAUTIONS ....................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 9 DRUG INTERACTIONS ....................................................................................................... 11 DOSAGE AND ADMINISTRATION ................................................................................... 12 OVERDOSAGE ...................................................................................................................... 14 ACTION AND CLINICAL PHARMACOLOGY ................................................................. 15 STORAGE AND STABILITY ............................................................................................... 16 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................
    [Show full text]
  • Mental Disorders and Illicit Drug Use Expert Group
    Global Burden of Disease Mental Disorders and Illicit Drug Use Expert Group Fiona Charlson, Louisa Degenhardt, Jennifer McLaren, Wayne Hall and Michael Lynskey Benzodiazepine-related mortality Illicit Drugs Discussion Paper No. 1 GBD2005 Mental Disorders and Illicit Drug Use Expert Group www.gbd.unsw.edu.au BENZODIAZEPINE-RELATED MORTALITY Fiona Charlson, Louisa Degenhardt, Jennifer McLaren, Wayne Hall and Michael Lynskey Illicit Drugs Discussion Paper No. 1 Recommended citation: Charlson, F., Degenhardt, L., McLaren, J., Hall, W., & Lynskey, M. (2008). Benzodiazepine- related mortality. Global Burden of Disease Mental Disorders and Illicit Drug Use Expert group, Illicit drugs discussion paper No. 1. National Drug and Alcohol Research Centre, University of NSW: Sydney. ISBN: 978 0 7334 2688 9 ©NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2008 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney,NSW 2052, Australia. GBD2005 Mental Disorders and Illicit Drug Use Expert Group www.gbd.unsw.edu.au Table of contents Summary and recommendations .............................................................................................. 1 1. Introduction
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2020) Revision 6 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2020) Revision 6 Annotated for Statistical Reporting Purposes CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers, sugar acetals and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer (including an anticaking agent) necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
    [Show full text]
  • Über Die Aussagesicherheit Der Substanzidentifizierung Mittels
    Über die Aussagesicherheit der Substanzidentifizierung mittels HPLC-DAD in der Systematischen Toxikologischen Analyse unter Verwendung einer selbsterstellten UV-Spektrenbibliothek mit 2.682 Einträgen D i s s e r t a t i o n zur Erlangung des akademischen Grades d o c t o r r e r u m n a t u r a l i u m (Dr. rer. nat.) im Fach Chemie eingereicht an der Mathematisch-Naturwissenschaftlichen Fakultät I der Humboldt-Universität zu Berlin von Dipl.-Chem. Matthias Herzler geboren am 23. Dezember 1966 in Münster/Westfalen Präsident der Humboldt-Universität zu Berlin Prof. Dr. Jürgen Mlynek Dekan der Mathematisch-Naturwissenschaftlichen Fakultät I Prof. Dr. Michael W. Linscheid Gutachter: 1. Prof. Dr. rer. nat. Fritz Pragst 2. Prof. Dr. rer. nat. Michael W. Linscheid 3. PD Dr. rer. nat. habil. Ulrich Demme Tag der mündlichen Prüfung: 17. März 2003 Inhaltsverzeichnis 1 EINLEITUNG ........................................................................................................................1 2 THEORETISCHE GRUNDLAGEN .....................................................................................4 2.1 Die Systematische Toxikologische Analyse .................................................................4 2.1.1 Zum Begriff der STA ..............................................................................................4 2.1.2 Toxikologische Relevanz........................................................................................5 2.1.3 Gesamtstrategie für die STA ...................................................................................7
    [Show full text]